Do Digestive Enzymes Actually Work? The Honest, Use-by-Use Answer

By Erin Rose · Updated July 20, 2026 · Methodology

Educational overview — not medical advice. No finding here should be read as a substitute for diagnosis or for prescribed pancreatic enzyme replacement therapy. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

Four claims, graded on their own evidence — not on each other

Digestive-enzyme marketing routinely blends a strong lactase finding, a real-but-scoped alpha-galactosidase finding, a strong-but-clinical PERT finding, and a thin broad-spectrum-blend pitch into one confident "supports healthy digestion" story. Separated honestly, using the primary endpoint of each trial and stating COI where it exists, they're four very different evidence states.

1. Lactase for lactose intolerance — the strongest thread

Two independently designed trials, both positive on their primary endpoint. Montalto et al. 2005 (n=30, double-blind, placebo-controlled, crossover milk challenge) found exogenous lactase significantly cut max breath H2 (12.07/13.97 vs 51.46 ppm placebo, P<0.001) and symptom score (0.36/0.96 vs 3.7, P<0.001). Ojetti et al. 2010 (n=60, randomized 3-arm) found tilactase normalized the lactose breath test significantly more than placebo, and more than a probiotic comparator (p<0.01); it also beat placebo on peak breath-hydrogen and symptom score (p<0.0001). Both are acute milk-challenge designs, not multi-week studies of everyday eating, and both are small — but the consistent, large effect size across two separate trial designs is real, strong evidence for this specific use. Full breakdown on the lactose-intolerance page.

2. Alpha-galactosidase for bean/legume/FODMAP gas — real, but scoped to the meal, not IBS

Di Stefano et al. 2007 (n=8 healthy volunteers, dose-response) found 1200 GalU alpha-galactosidase significantly reduced breath H2 and flatulence severity after a 420g bean test meal. Ganiats et al. 1994 (n=19, the classic Beano-brand trial) found significantly fewer flatulence events/hour with alpha-galactosidase (P=.016) — but found no significant difference on bloating or abdominal pain, an important nuance often lost in "Beano stops gas" marketing. Di Nardo et al. 2013 (n=52 children, dosed by body weight) found reduced global distress (p=0.02) and fewer days with moderate-severe bloating (p=0.03) — the authors themselves note "larger and longer trials are needed to confirm this result," and pediatric weight-based dosing shouldn't be extrapolated to adults. All three are real, RCT-backed findings scoped to an acute or short-term bean/legume/FODMAP gas trigger.

3. Pancreatic enzyme replacement therapy — strong evidence, wrong category for this page's shopping table

PERT has genuinely strong evidence for its actual indication: de la Iglesia-García et al. 2017's systematic review and meta-analysis (17 studies, 511 chronic pancreatitis patients) found PERT improved coefficient of fat absorption vs baseline (83.7% vs 63.1%, p<0.00001) and vs placebo (83.2% vs 67.4%, p=0.0001). Stern et al. 2000's withdrawal-design trial (n=74 CF/EPI patients) showed the flip side directly: withdrawing enzymes in diagnosed CF/EPI caused a large, significant rise in fecal fat (adult: 61.9 vs 2.3 g/day maintained on enzymes) — enzymes are not optional maintenance therapy in that population. Brady et al. 2006 (n=18 CF patients) found an enteric-coated, high-buffered formulation reduced fat excretion further than a non-buffered one. ⚠️ COI: the de la Iglesia-García meta-analysis discloses a co-author's consultancy and financial support from Abbott (Mylan), which manufactures Creon, a leading prescription PERT brand — disclosed here every time it's cited. All three trials are about diagnosed cystic fibrosis or chronic pancreatitis patients on prescription pancrelipase — never evidence that an OTC broad-spectrum blend is an alternative to, or equivalent dose of, prescribed PERT. See the dosage guide for the hard PERT-is-not-OTC boundary.

4. Broad-spectrum "digestive enzyme complex" blends — the thinnest evidence, and the most direct conflict of interest in the pack

This is where marketing outruns evidence the most. Majeed et al. 2018 (n=40, DigeZyme 50mg 3x/day, 60 days) reported statistically significant improvement across all efficacy parameters (P=.0033-.0401) — but ⚠️ the authors are founders/employees of Sami/Sabinsa, DigeZyme's manufacturer, a 100% author-manufacturer overlap and the most direct conflict of interest in this entire evidence pack. Ullah et al. 2023 (n=120, fungal-fermentation blend, 2 months) reported improved quality of life, but the abstract gives no quantitative effect size or p-value for its own primary endpoint — a real reporting gap. Levine et al. 2015 (n=16 healthy volunteers, lipase alone before a high-fat meal) is the cleanest "does it help healthy people" trial in the pack, and even its one positive finding is narrow: fullness ratings improved, but bloating, nausea, and gastric myoelectrical activity did not. Spagnuolo et al. 2017 (n=43 IBD-in-remission patients) tested a mixed beta-glucan/inositol/enzyme product, not enzymes alone, so its reported symptom improvement can't be attributed to the enzyme component in isolation. None of these four trials tested any of the three specific broad-spectrum products sold on this site's best-overall page.

What none of this supports

Every trial in this evidence base measures a narrow, specific outcome — breath-hydrogen levels, a symptom score, flatulence events per hour, coefficient of fat absorption, or a quality-of-life index. None measures disease reversal. "Digestive enzymes cure IBS," "heal your gut," or "detox" claims are marketing overreach not supported by any citation here — even lactase, the strongest-evidenced use case, only reduces symptoms from a specific dairy challenge; it does not cure lactose intolerance itself. Framing any of these findings as a general disease treatment or cure goes beyond what the underlying research shows.

Safety, briefly

Generally safe at studied OTC doses across all four buckets. Alpha-galactosidase and most broad-spectrum blend enzymes are commonly fungal-sourced (Aspergillus niger/oryzae) — a possible, generally low-risk allergy source. Some broad-spectrum blends contain porcine pancreatin — a real consideration for anyone avoiding pork. GI upset is documented, not just theoretical: in Hillilä 2016, more patients withdrew from the active alpha-galactosidase arm than placebo specifically from abdominal pain and diarrhea. And PERT is a medical therapy for a diagnosed disease — never a self-care substitute; anyone with EPI symptoms should see a gastroenterologist.

Compare Digestive Enzyme Products

If you're ready to buy, here's how the digestive enzyme products we track and verify compare on cost per dose.

Frequently asked questions

Related

• Digestive enzymes: what they are & who each one's for
• Lactase for lactose intolerance — the full breakdown
• Digestive enzyme dosage guide — units, timing, and the PERT boundary
• Best digestive enzymes — ranked within use case

Sources